1. Home
  2. ACON vs GNPX Comparison

ACON vs GNPX Comparison

Compare ACON & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACON
  • GNPX
  • Stock Information
  • Founded
  • ACON 2008
  • GNPX 2009
  • Country
  • ACON United States
  • GNPX United States
  • Employees
  • ACON N/A
  • GNPX N/A
  • Industry
  • ACON Retail: Computer Software & Peripheral Equipment
  • GNPX Biotechnology: Pharmaceutical Preparations
  • Sector
  • ACON Technology
  • GNPX Health Care
  • Exchange
  • ACON Nasdaq
  • GNPX Nasdaq
  • Market Cap
  • ACON 7.1M
  • GNPX 6.1M
  • IPO Year
  • ACON 2022
  • GNPX 2018
  • Fundamental
  • Price
  • ACON $12.39
  • GNPX $0.38
  • Analyst Decision
  • ACON Buy
  • GNPX Strong Buy
  • Analyst Count
  • ACON 2
  • GNPX 1
  • Target Price
  • ACON $481.00
  • GNPX $10.00
  • AVG Volume (30 Days)
  • ACON 370.3K
  • GNPX 6.0M
  • Earning Date
  • ACON 05-14-2025
  • GNPX 05-13-2025
  • Dividend Yield
  • ACON N/A
  • GNPX N/A
  • EPS Growth
  • ACON N/A
  • GNPX N/A
  • EPS
  • ACON N/A
  • GNPX N/A
  • Revenue
  • ACON $49,289.00
  • GNPX N/A
  • Revenue This Year
  • ACON N/A
  • GNPX N/A
  • Revenue Next Year
  • ACON $186.36
  • GNPX N/A
  • P/E Ratio
  • ACON N/A
  • GNPX N/A
  • Revenue Growth
  • ACON N/A
  • GNPX N/A
  • 52 Week Low
  • ACON $9.75
  • GNPX $0.22
  • 52 Week High
  • ACON $6,241.05
  • GNPX $4.09
  • Technical
  • Relative Strength Index (RSI)
  • ACON 33.77
  • GNPX 43.09
  • Support Level
  • ACON $9.75
  • GNPX $0.22
  • Resistance Level
  • ACON $13.69
  • GNPX $0.39
  • Average True Range (ATR)
  • ACON 2.54
  • GNPX 0.06
  • MACD
  • ACON 12.17
  • GNPX 0.00
  • Stochastic Oscillator
  • ACON 8.69
  • GNPX 31.23

About ACON Aclarion Inc.

Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The Company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

Share on Social Networks: